The Dominantly Inherited Alzheimer Network (DIAN), Core B: Clinical is responsible for the protocol implementation of all clinical operations for the research studies, including participant recruitment and retention, and protection;performing clinical evaluations including CDR and psychometric testing, completing imaging, blood and CSF collections, and offering genetic counseling and testing. The study of longitudinal progression of dominantly inherited Alzheimer disease will likely lead to a better understanding of the causes of Alzheimer disease. DIAN studies inform about potential methods of detecting AD and the sequence of events at the earliest stages of the illness, even before clinical symptoms have begun. The DIAN-Observational study will continue to support and enable preventative treatments to be tested. The Clinical Core will obtain highly sensitive clinical evaluations and psychometric testing to determine the earliest symptoms and progression rates. Novel computerized validated cognitive tests will be added to the cognitive battery. The longitudinal study of cognitive and clinical measures will be analyzed by estimated years to symptomatic onset and followed longitudinally to estimate progression and rates of change. The Clinical Core also will monitor and oversee imaging studies, blood and CSF to measure biomarker changes which may occur before symptoms. The data generated from these studies will be used by DIAN investigators to advance the understanding of the causes of Alzheimer disease, methods of early detection, and support ongoing and future preventative treatments.

Public Health Relevance

The Dominantly Inherited Alzheimer Network (DIAN), Core B: Clinical is responsible for the protocol implementation of all clinical operations for the research studies. The study of longitudinal progression of dominantly inherited Alzheimer disease will likely lead to a better understanding of the causes of this illness and the data generated from these studies will be used to advance methods of early detection and support ongoing and future preventative treatments.

Agency
National Institute of Health (NIH)
Type
Multi-Year Funded Research Project Cooperative Agreement (UF1)
Project #
2UF1AG032438-07
Application #
8863369
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Bateman, Randall J; Benzinger, Tammie L; Berry, Scott et al. (2016) The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement :
Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0163669
Soosman, Steffan K; Joseph-Mathurin, Nelly; Braskie, Meredith N et al. (2016) Widespread white matter and conduction defects in PSEN1-related spastic paraparesis. Neurobiol Aging 47:201-209
Lim, Yen Ying; Hassenstab, Jason; Cruchaga, Carlos et al. (2016) BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain 139:2766-2777
Miller-Thomas, Michelle M; Sipe, Adam L; Benzinger, Tammie L S et al. (2016) Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics 36:1147-63
Muenchhoff, Julia; Poljak, Anne; Thalamuthu, Anbupalam et al. (2016) Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. Sci Rep 6:29078
Tang, Mengxuan; Ryman, Davis C; McDade, Eric et al. (2016) Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol 15:1317-1325
Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0152082
Jin, Yan; Su, Yi; Zhou, Xiao-Hua et al. (2016) Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network. EURASIP J Bioinform Syst Biol 2016:12
Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2016) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord :

Showing the most recent 10 out of 29 publications